Search Result

Results for "

SOM

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Apoptosis (1) Calcium Channel (1) Casein Kinase (1) Connective Peptide (1) Endogenous Metabolite (1) Isotope-Labeled Compounds (1) Reactive Oxygen Species (ROS) (1) Small Interfering RNA (siRNA) (2) Somatostatin Receptor (7)
By Research Areas:	Cancer (7) Endocrinology (5) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16381

Pasireotide Maximum Cited Publications 6 Publications Verification SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-109110

Avasopasem manganese GC-4419; M-40419	Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
Avasopasem manganese (GC4419; M-40419) is a potent superoxide dismutase mimetic that rapidly and specifically converts O₂ ^- to hydrogen peroxide (H₂O₂), arresting the initiation of this cascade. Avasopasem manganese can be used for the research of severe oral mucositis (SOM*) and cancer .

HY-16381A

Pasireotide acetate 2 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-79135

Pasireotide ditrifluoroacetate Maximum Cited Publications 6 Publications Verification SOM230 ditrifluoroacetate; Pasireotide TFA salt	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-79136

Pasireotide L-aspartate salt Maximum Cited Publications 6 Publications Verification SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-108768

Pasireotide pamoate Maximum Cited Publications 6 Publications Verification SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381B

Pasireotide (diaspartate) SOM230 (diaspartate)	Somatostatin Receptor	Neurological Disease Cancer
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-RS05789

GRHL3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Connective Peptide	Others
GRHL3 Human Pre-designed siRNA Set A contains three designed siRNAs for GRHL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components GRHL3 siRNA-1: 5 nmol (HPLC) GRHL3 siRNA-2: 5 nmol (HPLC) GRHL3 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control: 5 nmol (HPLC)

GRHL3 Human Pre-designed siRNA Set A

Small Interfering RNA (siRNA) Connective Peptide

Others

GRHL3 Human Pre-designed siRNA Set A contains three designed siRNAs for GRHL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Components

GRHL3 siRNA-1: 5 nmol (HPLC)

GRHL3 siRNA-2: 5 nmol (HPLC)

GRHL3 siRNA-3: 5 nmol (HPLC)

siRNA Negative Control: 5 nmol (HPLC)

FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

GAPDH siRNA Positive Control: 5 nmol (HPLC)

GRHL3 Human Pre-designed siRNA Set A GRHL3 Human Pre-designed siRNA Set A

HY-RS18024

Sst Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Sst Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sst gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sst Mouse Pre-designed siRNA Set A Sst Mouse Pre-designed siRNA Set A

HY-175053

Pasireotide (aspartate) TFA SOM230 (aspartate) TFA	Somatostatin Receptor Apoptosis	Metabolic Disease
Pasireotide (aspartate) TFA, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide (aspartate) TFA can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide (aspartate) TFA also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-143788S

Pasireotide-d7 TFA SOM230-d7 TFA	Isotope-Labeled Compounds	Others
Pasireotide-d₇ (TFA) is the deuterium labeled Pasireotide TFA .

HY-B1035A

Levobunolol l-Bunolol	Adrenergic Receptor Casein Kinase Calcium Channel	Others
Levobunolol (l-Bunolol) is a non-selective β-adrenergic antagonist and vasodilator. By blocking calcium ion influx and reducing the sensitivity of vascular smooth muscle to calcium, Levobunolol effectively dilates the ciliary arteries and increases ocular blood flow, so it is widely used in research on glaucoma and ocular hypertension. Levobunolol inhibits the β-receptor signaling pathway and the expression of related proliferation markers (such as CK3, CK14, CK19, Ki67) in corneal cells. In rabbit models, Levobunolol not only does not inhibit corneal epithelial regeneration, but also accelerates the healing of mechanical injury without adverse effects. Levobunolol also inhibits histamine-induced vasoconstriction and intracellular calcium elevation, exhibiting unique vascular regulatory activity. Levobunolol protects ocular blood flow and promotes corneal repair .

HY-16381C

(2R)-Pasireotide (diaspartate) (2R)-SOM230 (diaspartate)	Endogenous Metabolite	Others
(2R)-Pasireotide ((2R)-SOM230) diaspartate exhibits a 40-fold higher affinity for somatostatin receptor 5 than other somatostatin analogs.

Cat. No.	Product Name	Target	Research Area